HighTower Advisors LLC Lowers Position in Dynavax Technologies Co. (NASDAQ:DVAX)

HighTower Advisors LLC cut its stake in Dynavax Technologies Co. (NASDAQ:DVAX) by 54.4% during the third quarter, HoldingsChannel reports. The fund owned 39,018 shares of the biopharmaceutical company’s stock after selling 46,466 shares during the quarter. HighTower Advisors LLC’s holdings in Dynavax Technologies were worth $441,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of DVAX. Louisiana State Employees Retirement System lifted its stake in shares of Dynavax Technologies by 3.0% during the second quarter. Louisiana State Employees Retirement System now owns 65,900 shares of the biopharmaceutical company’s stock worth $740,000 after buying an additional 1,900 shares during the period. AlphaCentric Advisors LLC boosted its holdings in shares of Dynavax Technologies by 6.1% in the 2nd quarter. AlphaCentric Advisors LLC now owns 130,000 shares of the biopharmaceutical company’s stock valued at $1,460,000 after acquiring an additional 7,500 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Dynavax Technologies by 1.0% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 118,037 shares of the biopharmaceutical company’s stock worth $1,326,000 after purchasing an additional 1,172 shares during the last quarter. Peregrine Capital Management LLC lifted its position in Dynavax Technologies by 1.3% during the second quarter. Peregrine Capital Management LLC now owns 534,454 shares of the biopharmaceutical company’s stock valued at $6,002,000 after purchasing an additional 6,952 shares during the period. Finally, Mizuho Markets Americas LLC boosted its stake in shares of Dynavax Technologies by 37.9% in the second quarter. Mizuho Markets Americas LLC now owns 1,175,107 shares of the biopharmaceutical company’s stock worth $13,196,000 after buying an additional 323,050 shares during the last quarter. 96.96% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, HC Wainwright restated a “buy” rating and set a $29.00 price target on shares of Dynavax Technologies in a research report on Friday, November 8th.

Dynavax Technologies Price Performance

Shares of Dynavax Technologies stock opened at $12.72 on Friday. The company has a debt-to-equity ratio of 0.33, a current ratio of 13.23 and a quick ratio of 12.34. Dynavax Technologies Co. has a 12 month low of $9.74 and a 12 month high of $15.01. The stock has a market capitalization of $1.67 billion, a P/E ratio of 97.85 and a beta of 1.33. The business has a 50 day simple moving average of $12.24 and a two-hundred day simple moving average of $11.51.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.